Logistics · infrastructure for the bad week
The shortage contingency file: the three-layer plan you build now, while everything is fine
The 2024–2025 shortage era taught this market one lesson worth keeping: supply disruptions reward the prepared and punish the improvising — and preparation is paperwork, not hoarding. The three layers, built in an afternoon: Layer one, buffer discipline with your current provider — know your ship day, know the refill lead time, and adopt the standing rule that reorders fire at two weeks of runway, never at empty, because every corridor’s middle leg stretches first in a squeeze. Layer two, the pre-vetted second lane — not a second subscription (that’s the household file’s different math) but a researched, verification-done shortlist: two alternates with pharmacy identity checked, current prices tier-read, and terms skimmed, so activation is days instead of the weeks a cold start costs. Layer three, molecule and lane flexibility on record — a prescriber conversation, held in calm weather, about which alternates are clinically acceptable for you (the bridge protocol exists precisely for this), plus a coverage check kept current so the brand lane’s status is a known quantity rather than a crisis-day research project. What the file is not: a stockpile (dating math defeats hoards — below), a gray-market map (shortages are counterfeit season), or a license to ration doses solo. Build it now; the whole point is never needing it in a hurry.
Layer one — buffer discipline: the two-week rule and the questions it requires
Most “shortage” pain is actually lead-time pain — a refill ordered at empty meeting a queue that grew — and buffer discipline dissolves it. Three facts to learn once and note in the diary: your provider’s ship day (ask support directly: “which day do refills leave the pharmacy?”), the reorder-to-doorstep interval under normal conditions (your own last two shipments are the data), and the refill trigger mechanics (auto-ship date versus manual reorder — auto-ship users confirm the date actually clears their two-week line). Then the standing rule: when the current vial’s remaining doses hit two weeks, the next order should already be in motion — not because disaster is likely, but because a two-week buffer converts every ordinary delay into a non-event and buys evaluation time for anything larger. The shortage-era archaeology shows what the alternative looked like: patients paying panic premiums for velocity that a calendar would have provided free.
Layer two — the second lane: vetting done in sunshine
A crisis-day provider search is the worst possible shopping trip — rushed, price-blind, verification skipped — so the contingency file does the trip now and shelves the results. The build: pick two alternates from the tier-labeled index (one same-molecule, one adjacent lane), and for each, complete the twenty-minute stack while nothing is wrong — pharmacy identity and board standing, current price against the value boards, terms skim for commitment traps, and a note on their stated intake-to-first-ship timeline. File the two one-page results in the records folder with a date — staleness matters, so the annual review refreshes them. The audited floors belong in this file by name: dose-proof flat pricing at $119 semaglutide / $139 tirzepatide, month-to-month with a 30-day written cancel (compounded; not FDA-approved) — a fallback lane whose price and terms you’ve already read is the entire difference between a contingency and a scramble. The audited fallback lane, priced today ↗ One honesty note: pre-vetting is research, not enrollment — most platforms can’t “hold” you dormant, so the file’s value is compressed activation, typically days once intake starts, versus the cold-start weeks of research-plus-corridor stacked together.
Layer three — flexibility on record: the calm-weather prescriber conversation
The most valuable shortage asset is a sentence in your chart: “if X becomes unavailable, patient may transition to Y per standard bridge.” Getting it costs one message in calm weather: ask your prescriber which alternates are clinically acceptable for you — the other molecule (the switch file covers the mechanics and the honest expectation reset), a different dose form, or the brand lane if coverage exists — and whether they’d document the contingency preference now. Pair it with a coverage status check you keep current: plan formularies and prior-auth rules shift at enrollment cycles, and knowing today whether the ~$25-class covered path is open to you (or firmly closed) removes the biggest crisis-day unknown — the churn file holds the renewal-season mechanics. Households running two patients coordinate this layer jointly: the household file’s redundancy logic doubles as shortage architecture, since two lanes already vetted is Layer two pre-built.
The three don’ts — where preparation curdles into risk
Don’t stockpile past the dating. Compounded vials carry conservative beyond-use dates for sterility reasons — a six-month hoard is a subscription to expired medication, and the money burned buying it was the contingency budget. The buffer rule’s two weeks, maybe a cycle beyond with prescriber blessing, is the honest ceiling. Don’t touch the gray market, especially during squeezes. Shortage seasons are counterfeit seasons — the quality-signals file’s entire framework exists because unverifiable product surges exactly when desperation peaks; research-chemical sites and peptide-forum sourcing are not Layer four, they’re the cliff. Don’t ration solo. Stretching intervals to conserve supply is a prescriber conversation (the interval file covers why improvised versions fail), and a documented temporary plan beats silent half-dosing every time — not least because your chart’s continuity is itself a contingency asset when a new provider someday reads it.
FAQ
How do I prepare for a GLP-1 shortage?
Three layers: a two-week reorder buffer with your current provider, two pre-vetted alternates with verification and pricing already done, and a documented prescriber conversation about acceptable molecule or lane switches — built in calm weather.
Should I stockpile compounded semaglutide or tirzepatide?
No — conservative beyond-use dates defeat hoarding; a two-week buffer (perhaps one cycle more with prescriber blessing) is the honest ceiling, with money better spent pre-vetting a second lane.
What if my medication becomes unavailable mid-course?
Activate the file: the documented bridge to an acceptable alternate, the pre-vetted second provider whose intake compresses to days, and the coverage status you’ve kept current — never gray-market sourcing or solo rationing.